Synopsis: The share of this company surged 16 percent after reporting 97 percent YoY profit growth, supported by strong U.S. launches, ANDA approvals, and expansion in complex injectables.
The share of this company, which is a leading Indian generic-focused injectable pharmaceutical company and a major global contract development and manufacturing organization, gained investor traction after a strong Q4.
With a market capitalization of Rs 35,395 crore, Gland Pharma Ltd’s share on Monday made a day high of Rs 2,170 per share, up around 16 percent up from its previous day’s close price of Rs 1,867 per share. The share of this company gave a return of 44 percent over the last year.
Result Overview and Dividend
- QoQ View: The revenue from operations grew by 3 percent to Rs 1,742.8 crore in Q4 FY26 from Rs 1,695.4 crore in Q3 FY26, and Adjusted EBITDA grew by 17 percent to Rs 524.4 crore in Q4 FY26 from Rs 449.0 crore in Q3 FY26. Accompanied by an Adjusted net profit (PAT) growth of 31 percent to Rs 366.7 crore in Q4 FY26 from Rs 279.7 crore in Q3 FY26.
- YoY View: The revenue from operations grew by 22 percent to Rs 1,742.8 crore in Q4 FY26 from Rs 1,424.9 crore in Q4 FY25, and Adjusted EBITDA grew by 51 percent to Rs 524.4 crore in Q4 FY26 from Rs 347.5 crore in Q4 FY2
- Fiscal Year Comparison: The revenue from operations grew by 14 percent to Rs 6,430.7 crore in FY26 from Rs 5,616.5 crore in FY25, and the annual Adjusted EBITDA margin scaled to 26 percent in FY26 from 23 percent in FY25. This was accompanied by an annual Adjusted net profit (PAT) margin expansion to 16 percent in FY26 from 12 percent in FY25, resulting in an Adjusted PAT growth of 50 percent to Rs 1,045.5 crore from Rs 698.5 crore.
- Dividend: The Board of Gland Pharma has recommended a final dividend of Rs 20 per equity share with a face value of Re 1 for FY26, translating into a 2,000 percent dividend payout. The dividend remains subject to shareholder approval at the upcoming annual general meeting.
Q4 business performance
R&D Spend Supports Complex Pipeline: The company continued to strengthen its product development pipeline during Q4 FY26, with R&D expenses standing at Rs 506 million, accounting for 4 percent of base business revenue. The spending remained focused on complex product development and increasing regulatory filings, highlighting the company’s strategy to build a differentiated portfolio in regulated markets.
U.S. Launches and ANDA Approvals Stay Strong: During the quarter, the company launched five molecules in the U.S., including Dalbavancin and Brimonidine, taking the total launches for FY26 to 31 products. It also filed eight ANDAs and received 11 approvals in Q4 FY26. For the full year, 24 ANDAs were filed, and 28 approvals were received, bringing cumulative U.S. filings to 388 ANDAs, of which 337 have been approved, while 51 remain pending.
Complex Injectables Pipeline Expands: The company also continued to expand its complex injectable and specialty pipeline. Six in-house complex products have already been commercialized, while three additional products are awaiting approvals. Alongside this, 15 products are under co-development partnerships, including seven 505(b)(2) products and eight ANDAs, with commercialization expected to begin from FY28 onward.
RTU Bags and GLP-1 Business Gain Traction: In the Ready-to-Use infusion bag segment, the company has filed 21 products and secured approvals for 18 so far, while another 11 products remain under development. The portfolio currently targets a U.S. market opportunity of nearly $634 million.
Additionally, the company expanded its GLP-1 and insulin analog presence with the launch of Liraglutide in the U.S., while pen and cartridge manufacturing capacity increased to 140 million units annually. The company also secured a new oncology-focused CDMO contract based on Nano Drug Delivery Systems.
About the Company
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 2,000% Dividend: Pharma stock skyrockets 16% after reporting 97% YoY net profit growth appeared first on Trade Brains.